Christina Christoffersen

List of Publications by Year
in descending order

62	2,969	201674	168389
papers	citations	27 h-index	53 g-index

66	66	66	3755
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9613-9618.	7.1	512
2	Cardiac Lipid Accumulation Associated with Diastolic Dysfunction in Obese Mice. Endocrinology, 2003, 144, 3483-3490.	2.8	329
3	Induction of Atherosclerosis in Mice and Hamsters Without Germline Genetic Engineering. Circulation Research, 2014, 114, 1684-1689.	4.5	223
4	Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice. Journal of Biological Chemistry, 2008, 283, 1839-1847.	3.4	165
5	Isolation and characterization of human apolipoprotein M-containing lipoproteins. Journal of Lipid Research, 2006, 47, 1833-1843.	4.2	157
6	Hypoxia-Inducible Factor-1Î± Expression in Macrophages Promotes Development of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1782-1790.	2.4	113
7	Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents. Cell Metabolism, 2016, 24, 234-245.	16.2	103
8	Impaired endothelial barrier function in apolipoprotein Mâ€deficient mice is dependent on sphingosineâ€1â€phosphate receptor 1. FASEB Journal, 2016, 30, 2351-2359.	0.5	99
9	Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. Atherosclerosis, 2012, 221, 91-97.	0.8	92
10	The Signal Peptide Anchors Apolipoprotein M in Plasma Lipoproteins and Prevents Rapid Clearance of Apolipoprotein M from Plasma. Journal of Biological Chemistry, 2008, 283, 18765-18772.	3.4	64
11	HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver. JCI Insight, 2016, 1, e87058.	5.0	59
12	Chamber-Dependent Expression of Brain Natriuretic Peptide and Its mRNA in Normal and Diabetic Pig Heart. Hypertension, 2002, 40, 54-60.	2.7	57
13	Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. Journal of Biological Chemistry, 2018, 293, 7408-7422.	3.4	57
14	Sphingosine-1-phosphate reduces ischaemiaâ€“reperfusion injury by phosphorylating the gap junction protein Connexin43. Cardiovascular Research, 2016, 109, 385-396.	3.8	55
15	The Apolipoprotein M/S1P Axis Controls Triglyceride Metabolism and Brown Fat Activity. Cell Reports, 2018, 22, 175-188.	6.4	54
16	High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression. Atherosclerosis, 2017, 257, 29-37.	0.8	51
17	Apolipoprotein M. Current Opinion in Lipidology, 2013, 24, 295-300.	2.7	50
18	Altered Metabolism of LDL in the Arterial Wall Precedes Atherosclerosis Regression. Circulation Research, 2015, 117, 933-942.	4.5	46

#	Article	IF	Citations
19	Apolipoprotein M-bound sphingosine-1-phosphate regulates bloodâ€“brain barrier paracellular permeability and transcytosis. ELife, 2019, 8, .	6.0	43
20	Opposing Effects of Apolipoprotein M on Catabolism of Apolipoprotein Bâ€“Containing Lipoproteins and Atherosclerosis. Circulation Research, 2010, 106, 1624-1634.	4.5	42
21	Apolipoprotein M in lipid metabolism and cardiometabolic diseases. Current Opinion in Lipidology, 2015, 26, 48-55.	2.7	42
22	The plasma concentration of HDL-associated apoM is influenced by LDL receptor-mediated clearance of apoB-containing particles. Journal of Lipid Research, 2012, 53, 2198-2204.	4.2	39
23	Galnt11 regulates kidney function by glycosylating the endocytosis receptor megalin to modulate ligand binding. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25196-25202.	7.1	38
24	Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway. Diabetes, 2019, 68, 1329-1340.	0.6	33
25	Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1287-1292.	2.4	32
26	Familial hypercholesterolaemia: cholesterol efflux and coronary disease. European Journal of Clinical Investigation, 2016, 46, 643-650.	3.4	30
27	Apolipoprotein M mediates sphingosine-1-phosphate efflux from erythrocytes. Scientific Reports, 2017, 7, 14983.	3.3	30
28	Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ Repair. Developmental Cell, 2020, 53, 677-690.e4.	7.0	25
29	A Novel Perspective on the ApoM-S1P Axis, Highlighting the Metabolism of ApoM and Its Role in Liver Fibrosis and Neuroinflammation. International Journal of Molecular Sciences, 2017, 18, 1636.	4.1	22
30	Regional distribution and severity of arterial calcification in patients with chronic kidney disease stages 1â€“5: a cross-sectional study of the Copenhagen chronic kidney disease cohort. BMC Nephrology, 2020, 21, 534.	1.8	21
31	Endothelial-Specific Loss of Sphingosine-1-Phosphate Receptor 1 Increases Vascular Permeability and Exacerbates Bleomycin-induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 38-52.	2.9	21
32	Protein unfolding allows use of commercial antibodies in an apolipoprotein M sandwich ELISA. Journal of Lipid Research, 2015, 56, 754-759.	4.2	17
33	Functional brown adipose tissue and sympathetic activity after cold exposure in humans with type 1 narcolepsy. Sleep, 2018, 41, .	1.1	17
34	Apolipoprotein M in patients with chronic kidney disease. Atherosclerosis, 2018, 275, 304-311.	0.8	15
35	Effects of apolipoprotein M in uremic atherosclerosis. Atherosclerosis, 2017, 265, 93-101.	0.8	14
36	Apolipoprotein M/sphingosine-1-phosphate: novel effects on lipids, inflammation and kidney biology. Current Opinion in Lipidology, 2019, 30, 212-217.	2.7	13

#	Article	IF	Citations
37	Subclinical atherosclerosis in patients with cyanotic congenital heart disease. International Journal of Cardiology, 2019, 277, 97-103.	1.7	13
38	Apolipoprotein Mâ€"A Marker or an Active Player in Type II Diabetes?. Frontiers in Endocrinology, 2021, 12, 665393.	3.5	13
39	Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system. Atherosclerosis, 2021, 334, 76-84.	0.8	12
40	Apolipoprotein E Deficiency Increases Remnant Lipoproteins and Accelerates Progressive Atherosclerosis, But NotÂXanthoma Formation, in Gene-Modified Minipigs. JACC Basic To Translational Science, 2017, 2, 591-600.	4.1	11
41	Molecular Characterization of Microvesicular and Macrovesicular Steatosis Shows Widespread Differences in Metabolic Pathways. Lipids, 2019, 54, 109-115.	1.7	11
42	Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology, 2019, 19, 228.	2.0	11
43	Circulating cord blood HDL-S1P complex preserves the integrity of the feto-placental vasculature. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158632.	2.4	11
44	The apoM/S1P Complexâ€"A Mediator in Kidney Biology and Disease?. Frontiers in Medicine, 2021, 8, 754490.	2.6	11
45	Diurnal regulation of sphingolipids in blood. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 304-311.	2.4	10
46	Apolipoprotein M and Sphingosine-1-Phosphate Receptor 1 Promote the Transendothelial Transport of High-Density Lipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, e468-e479.	2.4	10
47	Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: the Thousand & 1 Study. European Journal of Endocrinology, 2020, 182, 481-488.	3.7	10
48	Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification. PLoS ONE, 2021, 16, e0260417.	2.5	9
49	ApoB and apoM â€" New aspects of lipoprotein biology in uremia-induced atherosclerosis. European Journal of Pharmacology, 2017, 816, 154-160.	3.5	8
50	Effect of menopause and exercise training on plasma apolipoprotein M and sphingosine-1-phosphate. Journal of Applied Physiology, 2019, 126, 214-220.	2.5	8
51	Apolipoprotein M and Risk of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3046-3057.	3.6	8
52	Increased plasma apoM levels impair triglyceride turnover in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158969.	2.4	7
53	Diurnal gene expression of lipolytic natriuretic peptide receptors in white adipose tissue. Endocrine Connections, 2015, 4, 206-214.	1.9	4
54	Study protocol: long-term effect of the New Nordic Renal Diet on phosphorus and lipid homeostasis in patients with chronic kidney disease, stages 3 and 4: a randomised controlled trial. BMJ Open, 2021, 11, e045754.	1.9	4

#	Article	IF	Citations
55	The metabolic signature of cardiovascular disease and arterial calcification in patients with chronic kidney disease. Atherosclerosis, 2022, 350, 109-118.	0.8	3
56	Left ventricular structure and function in patients with chronic kidney disease assessed by 3D echocardiography: the CPH-CKD ECHO study. International Journal of Cardiovascular Imaging, 2021, , 1.	1.5	3
57	Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes. Diabetes Research and Clinical Practice, 2022, 189, 109943.	2.8	2
58	The Arg82Cys Polymorphism of the Protein Nepmucin Implies a Role in HDL Metabolism. Journal of the Endocrine Society, 2022, 6, bvac034.	0.2	1
59	Effect of insulin on natriuretic peptide gene expression in porcine heart. Peptides, 2020, 131, 170370.	2.4	0
60	MO339KIDNEY DERIVED APOM AND ITS ROLE IN ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
61	FC 060METABOLIC PROFILING AS A MARKER OF CARDIOVASCULAR DISEASE AND ARTERIAL CALCIFICATION IN THE COPENHAGEN CHRONIC KIDNEY DISEASE COHORT. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
62	MO145CAROTID PLAQUE THICKNESS COMPARED WITH SEVERITY OF CAROTID AND CORONARY ARTERY CALCIFICATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 3. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0